Cargando…
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction
Background: Elevated interleukin-6 (IL-6) and complement activation are associated with detrimental effects of inflammation in coronary artery disease (CAD). The complement anaphylatoxins C5a and C3a interact with their receptors; the highly inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated t...
Autores principales: | Orrem, Hilde L., Nilsson, Per H., Pischke, Søren E., Kleveland, Ola, Yndestad, Arne, Ekholt, Karin, Damås, Jan K., Espevik, Terje, Bendz, Bjørn, Halvorsen, Bente, Gregersen, Ida, Wiseth, Rune, Andersen, Geir Ø., Ueland, Thor, Gullestad, Lars, Aukrust, Pål, Barratt-Due, Andreas, Mollnes, Tom E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143659/ https://www.ncbi.nlm.nih.gov/pubmed/30258440 http://dx.doi.org/10.3389/fimmu.2018.02035 |
Ejemplares similares
-
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
por: Ueland, Thor, et al.
Publicado: (2018) -
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
por: Helseth, Ragnhild, et al.
Publicado: (2021) -
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
por: Woxholt, Sindre, et al.
Publicado: (2023) -
Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases—C3 or C5 emerge together with CD14 as promising targets
por: Barratt-Due, Andreas, et al.
Publicado: (2017) -
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
por: Anstensrud, Anne Kristine, et al.
Publicado: (2019)